No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

Robby Soave and Niall Stanage weigh in on debate of using A.I. to develop mRNA vaccines to target cancer. #AI #mrnavaccines ...

MRNA’s first problem is the lack of near-term catalysts beyond infectious disease vaccines. The stock often swings on disease outbreaks, such as H5N1 avian flu last year, but this is unlikely to ...

President Donald Trump announced a $500billion investment for private companies to develop artificial intelligence tools to ...

We recently published a list of These 10 Firms Were Thursday’s Top Performers. In this article, we are going to take a look ...

Real-time index price for TSX 60 Index (TXSX), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

Following the lead of previous work on mRNA-based vaccines, therapies for spinal cord injuries and more, the method relies upon mineral-coated microparticles to deliver mRNA that encodes for ...

New documents clarify how the FDA plans to regulate AI-enabled devices, experts say, but several important questions remain ...

Members of the family who own OxyContin maker Purdue Pharma, and the company itself, agreed to pay up to $7.4 billion in a new settlement to lawsuits over the toll of the powerful prescription ...

Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 12,155 calls trading, 1.0x expected, and implied vol increasing almost 2 ...

Stocks closed solidly higher on Thursday for the fourth straight session as investor optimism about the Trump administration continues to run high.

The global gene transfer technologies market, valued at US$3.63 billion in 2023, is forecasted to grow at a robust CAGR of 9.7%, ...